Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Addiction Reports
Erschienen in:

01.06.2019 | Dissociation and Addictive Behaviors (J Billieux and A Schimmenti, Section Editors)

New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

verfasst von: Fabrizio Schifano, Flavia Napoletano, Stefania Chiappini, Laura Orsolini, Amira Guirguis, John Martin Corkery, Stefania Bonaccorso, Angelo Ricciardi, Norbert Scherbaum, Alessandro Vento

Erschienen in: Current Addiction Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

A significant increase in the number, type and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic substances have historically been used in order to achieve altered states of consciousness such as dissociative states. We aimed here at describing both a large number of novel ketamine-like dissociatives and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing the acute/long-term clinical scenarios most commonly associated with their intake.

Recent Findings

An updated overview of the clinical and clinical pharmacological issues related to some of the most popular NPS categories has been provided, describing both psychosis and remaining psychopathological issues related to them.

Conclusions

Although the complex link between NPS and psychiatric illnesses is yet to be fully understood, NPS misuse is now a significant clinical issue and an increasing challenge for clinicians working in both mental health and emergency departments.
Literatur
1.
2.
Schifano F. Recent changes in drug abuse scenarios: the new/novel psychoactive substances (NPS) phenomenon. Brain Sci. 2018;8(12).
3.
Jaffe JH. Drug addiction and drug abuse. In: Goodman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw Hill; 1990. p. 522–73.
4.
• Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8(3). This review focused on the aetiology of Hallucinogen Persisting Perception Disorder induction, the possible hallucinogens involved, the clinical features, the possible psychiatric comorbidities, and the available potential therapeutic strategies.
5.
Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15–26.CrossRefPubMedPubMedCentral
6.
Barker SA. N, N-dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function. Front Neurosci. 2018;12:536.CrossRefPubMedPubMedCentral
7.
Strassman R. DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experiences. Vermont: Park Street Press Rochester; 2001.
8.
Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138–43.CrossRefPubMedPubMedCentral
9.
Bleuler E. Dementia praecox or the group of schizophrenias. New York, NY: International Universities Press; 1950.
10.
Maatz A, Hoff P, Angst J. Eugen Bleuler’s schizophrenia—a modern perspective. Dialogues Clin Neurosci. 2015;17(1).
11.
Moskowitz A, Heim G. Eugen Bleuler’s dementia praecox or the group of schizophrenias (1911): a centenary appreciation and reconsideration. Schizophr Bull. 2011;37(3):471–9.CrossRefPubMedPubMedCentral
12.
Dell PF, O’Neil JA. Dissociation and the dissociative disorders: DSM-V and beyond. New York, NY: Routledge; 2009.
13.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.CrossRef
14.
•• Lyssenko L, Schmahl C, Bockhacker L, Vonderlin R, Bohus M, Kleindienst N. Dissociation in psychiatric disorders: a meta-analysis of studies using the Dissociative Experiences Scale. Am J Psychiatry. 2018;175:37–46. This meta-analysis provides information on the prevalence and distribution of dissociative symptoms within different categories of mental disorders.CrossRefPubMed
15.
St John-Smith P, McQueen D, Edwards L, Schifano F. Classical and novel psychoactive substances: rethinking drug misuse from an evolutionary psychiatric perspective. Hum Psychopharmacol. 2013;28(4):394–401.CrossRefPubMed
16.
Orsolini L, St John-Smith P, McQueen D, Papanti D, Corkery J, Schifano F. Evolutionary considerations on the emerging subculture of the E-psychonauts and the novel psychoactive substances: a comeback to the shamanism? Curr Neuropharmacol. 2017;15(5):731–7.CrossRefPubMedPubMedCentral
17.
Hofmann A. translated from the original German (LSD Ganz persönlich) by J. Ott. MAPS-Vol. 6, No. 69 (Summer 1969).
18.
Hofmann A. LSD – mein Sorgenkind. München, dtv, 1993.
19.
Corazza O, Schifano F. Ketamine-induced ‘near-death experience’ states in a sample of 50 misusers. Subst Use Misuse. 2010;45:916–24.CrossRefPubMed
20.
Abdulrahim D, Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 2015.
21.
Caloro M, Calabrò G, de Pisa E, Rosini E, Kotzalidis GD, Lonati D, et al. Combined NMDA inhibitor use in a patient with multisubstance-induced psychotic disorder. J Addict Med. 2018;12(3):247–51.CrossRefPubMed
22.
Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, et al. Phenomenon of new drugs on the internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol. 2012;27(2):145–9.CrossRefPubMed
23.
Corazza O, Assi S, Schifano F. From ‘special K’ to ‘special M’: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther. 2013;19(6):454–60.CrossRefPubMedPubMedCentral
24.
• Hearne E, Van Hout MC. ‘Trip-Sitting’ in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs. 2016;48(4):233–42. This paper provides information relating to the use of dissociative novel psychoactive substances within the cyber drug user community.CrossRefPubMed
25.
Orsolini L, Ciccarese M, Papanti D, De Berardis D, Guirguis A, Corkery JM, et al. Psychedelic fauna for psychonaut hunters: a mini-review. Front Psychiatry. 2018;9:153.CrossRefPubMedPubMedCentral
26.
• Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry. 2017;8:240. This review focuses on the psychopathological background, the aetiological hypotheses, and psychopharmacological approaches towards the hallucinogen-persisting perception disorder, including its association with the intake of some novel psychoactive substances.CrossRefPubMedPubMedCentral
27.
Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97–132.CrossRefPubMedPubMedCentral
28.
•• Schifano F, Papanti GD, Orsolini L, Corkery JM. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Expert Rev Clin Pharmacol. 2016;9(7):943–54 This paper provides an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens.CrossRefPubMed
29.
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci. 2016;10:153.CrossRefPubMedPubMedCentral
30.
Ott J, Bigwood J. Teonanacatl hallucinogenic mushrooms of North America. Seattle, WA: Madrona Publishers; 1978.
31.
Schultes RE, Hofmann A. Plants of the gods: origins of hallucinogenic use. New York: Alfred van der Marck Editions; 1979.
32.
Pettigrew J. Iconography in Bradshaw rock art: breaking the circularity. Clin Exp Optom. 2011;94(5):403–17.CrossRefPubMed
33.
Turton S, Nutt DJ, Carhart-Harris RL. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Curr Drug Abuse Rev. 2014;7(2):117–27.CrossRefPubMed
34.
Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on a oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33(25):10544–51.CrossRefPubMedPubMedCentral
35.
Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 2010;5(8):e12412.CrossRefPubMedPubMedCentral
36.
Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012;123(1–3):132–40.CrossRefPubMed
37.
Bickel M, Ditting T, Watz H, Roesler A, Weidauer S, Jacobi V, et al. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after ‘magic mushroom’ abuse. Eur J Emerg Med. 2005;12(6):306–8.CrossRefPubMed
38.
El-Seedi HR, De Smet PA, Beck O, Possnert G, Bruhn JG. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005;101(1–3):238–42.CrossRefPubMed
39.
Bruhn JG, De Smet PA, El-Seedi HR, Beck O. Mescaline use for 5700 years. Lancet. 2002;359(9320):1866.CrossRefPubMed
40.
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005;58(8):624–31.CrossRefPubMed
41.
Lu BY, Woofter C, Escalona R. A case of prolonged peyote-induced psychosis resolved by sleep. J Clin Psychiatry. 2004;65(10):1433–4.CrossRefPubMed
42.
Dobkin de Rios M. Ayahuasca–the healing vine. Int J Soc Psychiatry. 1971 Winter;17(4):256–69.CrossRefPubMed
43.
• Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JA, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol. 2015;25(4):483–92. This paper suggests that regular use of psychedelic drugs could potentially lead to structural changes in brain areas supporting attentional processes, self-referential thought, and internal mentation.CrossRefPubMed
44.
Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, et al. Human psychopharmacology of hoasca, a a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996;184(2):86–94.CrossRefPubMed
45.
De Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, et al. Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp. 2012;33(11):2550–60.CrossRefPubMed
46.
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78(8):544–53.CrossRefPubMed
47.
Sjobergand BM Jr, Hollister LE. The effects of psychotomimetic drugs on primary suggestibility. Psychopharmacology. 1965;8(4):251–62.CrossRef
48.
Middlefell R. The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry. 1967;113(496):277–80.CrossRefPubMed
49.
50.
Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. LSD enhances suggestibility in healthy volunteers. Psychopharmacology. 2015;232(4):785–94.CrossRefPubMed
51.
Zentner M, Grandjean D, Scherer KR. Emotions evoked by the sound of music: characterization, classification, and measurement. Emotion. 2008;8(4):494–521.CrossRefPubMed
52.
Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PloS One. 8:e63972.
53.
Berrens Z, Lammers J, White C. Rhabdomyolysis after LSD ingestion. Psychosomatics. 2010;51(4):356–356.e3.CrossRefPubMed
54.
Raval MV, Gaba RC, Brown K, Sato KT, Eskandari MK. Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. J Vasc Interv Radiol. 2008;19(8):1227–30.CrossRefPubMed
55.
Bernhard MK, Ulrich K. Recurrent cortical blindness after LSD-intake. Fortschr Neurol Psychiatr. 2009;77(2):102–4.CrossRefPubMed
56.
• Graziano S, Orsolini L, Rotolo MC, Tittarelli R, Schifano F, Pichini S. Herbal highs: review on psychoactive effects and neuropharmacology. Curr Neuropharmacol. 2017;15(5):750–61. This review focuses on the psychoactive effects and neuropharmacology of the most popular “herbal highs”, considering both the subjective and eventual secondary effects, including intoxications and fatalities as well.CrossRefPubMedPubMedCentral
57.
58.
Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, et al. Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2015;56(2):129–39.CrossRefPubMed
59.
Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M. A fatal poisoning involving Bromo-dragonfly. Forensic Sci Int. 2009;183(1–3):91–6.CrossRefPubMed
60.
Balíková M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int. 2005;153(1):85–91.CrossRefPubMed
61.
Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, et al. Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One. 2016;11(6):e0157021.CrossRefPubMedPubMedCentral
62.
• Wallach J, Brandt SD. 1,2-Diarylethylamine- and ketamine-based new psychoactive substances. In: Handbook of experimental pharmacology. Berlin, Heidelberg: Springer; 2018. This chapter described some dissociative NPS having emerged on the market in recent years, considering their pharmacology and effects.
63.
Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal. 2014;6(7–8):614–32.CrossRefPubMed
64.
Halberstadt AL, Slepak N, Hyun J, Buell MR, Powell SB. The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology. 2016;233(7):1215–25.CrossRefPubMedPubMedCentral
65.
Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacol (Berl). 2012;223(1):1–15.CrossRef
66.
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, et al. The ketamine analogue methoxetamine and 3-and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PloS One. 2013;8(3):e59334.CrossRefPubMedPubMedCentral
67.
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug—sernyl. AMA Arch Neurol Psychiatry. 1959;81(3):363–9.CrossRefPubMed
68.
Vollenweider FX, Leenders KL, Øye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and I-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7(1):25–38.CrossRefPubMed
69.
Bonta IL. Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor. Med Hypotheses. 2004;62(1):23–8.CrossRefPubMed
70.
• Tracy D, Wood DM, Baumeister D. Novel psychoactive substances: types, mechanisms of action, and effects. BMJ. 2017;356:i6848. This paper reviews the recent literature regarding NPS, classifying them into their major groupings and providing information on the desired effects of these compounds, their pharmacology, and the risks associated with their use.CrossRefPubMed
71.
Waelbers T, Polis I, Vermeire S, Dobbeleir A, Eersels J, De Spiegeleer B, et al. 5-HT2A receptors in the feline brain: 123I-5-I-R91150 kinetics and the influence of ketamine measured with micro-SPECT. J Nucl Med. 2013;54:1428–33.CrossRefPubMed
72.
Nishimura M, Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett. 1999;274:131–4.CrossRefPubMed
73.
74.
Corazza O. Near-death experiences: exploring the mind-body connection. London/New York: Routledge; 2008.CrossRef
75.
Jansen KLR. Ketamine: dreams and realities. MAPS: Sarasota, FL; 2011.
76.
Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the ‘K-hole’; overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol. 2008;28:114–6.CrossRefPubMed
77.
Comer NL, Madow L, Dixon JL. Observation of sensory deprivation in a life-threatening situation. Am J Psychiat. 1967;124:164–9.CrossRefPubMed
78.
Greyson B, Stevenson I. The phenomenology of near-death experiences. Am J Psychiat. 1980;137:1193–6.CrossRefPubMed
79.
Moody RA. Life after life. Atlanta, GA: Mockingbird Books; 1975.
80.
Persinger M. Religious and mystical experiences as artefacts of temporal lobe function: a general hypothesis. Percept Motor Skills. 1983;57:1255–62.CrossRefPubMed
81.
Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99:1450–61.CrossRefPubMed
82.
Luciano RL, Perazella MA. Nephrotoxic effects of designer drugs: synthetic is not better! Nat Rev Nephrol. 2014;10:314–24.CrossRefPubMed
83.
Corkery J, Claridge H, Loi B, Goodair C, Schifano F. Drug related deaths in the UK. NPSAD Annual Report 2013. London: International Centre for Drug Policy, St. George’s University of London; 2014.
84.
85.
86.
87.
Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, et al. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med. 2012;60(1):97–9.CrossRefPubMed
88.
Dargan PI, Tang HC, Liang W, Wood DM, Yew DT. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol. 2014;52:176–80.CrossRef
89.
EMCDDA. Risk assessments. Methoxetamine. Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino) cyclohexanone (methoxetamine) in the framework of the council decision on new psychoactive substances. European Monitoring Centre for Drugs and Drug Addiction: Lisbon; 2014.
90.
Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F. Special M related fatalities in the UK. Res Adv Psychiatry. 2014;1(Suppl. 1):38.
91.
Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F. Methoxetamine-related deaths in the UK: an overview. Hum Psychopharmacol. 2015;30(4):244–8.CrossRefPubMed
92.
Greifenstein FE, Yoshitake J, DeVault M, Gajewski JE. A study of 1-aryl cyclo hexyl amine for anaesthesia. Anasth Analog. 1958;5:283.
93.
Lear E. Intravenous anaesthesia: a survey of newer agents. Anaesth Analog. 1968;47:154.
94.
Domino EF. Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists. J Psychopharmacol. 1992;6:418–24.CrossRefPubMed
95.
96.
Burns RS, Lerner SE. Causes of phencyclidine-related deaths. Clin Toxicol. 1978b;12(4):463–81.CrossRefPubMed
97.
Burns RS, Lerner SE, Corrado R, James SH, Schnoll SH. Phencyclidine–states of acute intoxication and fatalities. West J Med. 1975;123(5):345–9.PubMedPubMedCentral
98.
DeRoux SJ, Sgarlato A, Marker E. Phencyclidine: a 5-year retrospective review from the New York City Medical Examiner’s Office. J Forensic Sci. 2011;56(3):656–9.CrossRefPubMed
99.
Eastman JW, Cohen SN. Hypertensive crisis and death associated with phencyclidine poisoning. JAMA. 1975;231(12):1270–1.CrossRefPubMed
100.
Noguchi TT, Nakamura GR. Phencyclidine-related deaths in Los Angeles County, 1976. J Forensic Sci. 1978;23(3):503–7.PubMed
101.
Pestaner JP, Southall PE. Sudden death during arrest and phencyclidine intoxication. Am J Forensic Med Pathol. 2003;24(2):119–22.PubMed
102.
Poklis A, Graham M, Maginn D, Branch CA, Gantner GE. Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners’ cases from 1977 through 1986. Am J Drug Alcohol Abuse. 1990;16(3–4):265–74.CrossRefPubMed
103.
Miller SC. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol. 2005;10(4):325–7.CrossRefPubMed
104.
Spangler DC, Loyd CM, Skor EE. Dextromethorphan: a case study on addressing abuse of a safe and effective drug. Subst Abuse Treat Prev Policy. 2016;11:22.CrossRefPubMedPubMedCentral
105.
Sheridan DC, Hendrickson RG, Beauchamp G, Laurie A, Fu R, Horowitz BZ. Adolescent intentional abuse ingestions. Overall 10-year trends and regional variation. Pediatr Emer Care. 2016;00:00–0.
106.
Karami S, Major JM, Calderon S, McAninch JK. Trends in dextromethorphan cough and cold products: 2000–2015 National Poison Data System intentional abuse exposure calls. Clin Toxicol (Phila). 2018;56(7):656–63.CrossRef
107.
Storck M, Black L, Liddell M. Inhalant abuse and dextromethorphan. Child Adolesc Psychiatric Clin N Am. 2016;25(3):497–508.CrossRef
108.
Romanelli F, Smith K. Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc. 2009;49(2):e20–7.CrossRef
109.
Martinak B, Bolis RA, Ryne J, Fargason RE, Birur B. Dextromethorphan in cough syrup: the poor man’s psychosis. Psychopharmacol Bull. 2017;47(4):59–63.PubMedPubMedCentral
110.
Roy AK, Hsieh C, Crapanzano K. Dextromethorphan addiction mediated through the NMDA system: common pathways with alcohol? J Addict Med. 2015;9:499–501.CrossRefPubMed
111.
Levine DA. ‘Pharming’: the abuse of prescription and over-the-counter drugs in teens. Curr Opin Pediatr. 2007;19(3):270–4.CrossRefPubMed
112.
Ahmed G, Saleem MD, Naim H. How many deaths before we put cough syrups behind the counter? Perspect Public Health. 2014;134(6):309.CrossRefPubMed
113.
Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Brit J Psychiatry. 2012;200(3):238–44.CrossRef
114.
Pahnke WN, Kurland AA, Goodman LE, Richards WA. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther. 1969;9:144–52.PubMed
115.
Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970;212(11):1856–63.CrossRefPubMed
116.
Pahnke WN, Kurland AA, Unger S, Savage C, Wolff MC, Goodman LE. Psychedelic therapy (utilizing LSD) with cancer patients. J Psychedelic Drugs. 1970;3:63–75.CrossRef
117.
Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8(3):129–44.CrossRefPubMed
118.
Griffiths R. Psilocybin, mystical-type experiences, and the treatment of symptoms of anxiety and depression in patients with a life-threatening cancer diagnosis. Presentation at the 168th Annual Meeting of the American Psychiatric Association, Abstract 1162.
119.
Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic sub- receptors. Biol Psychiatry. 2012;72(11):898–906.CrossRefPubMed
120.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–40.CrossRefPubMed
121.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept trial. J Psychopharmacol. 2015;29(3):289–99.CrossRefPubMed
122.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–92.CrossRefPubMedPubMedCentral
123.
Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66:1920–2.CrossRefPubMed
124.
Savage C. Lysergic acid diethylamide; a clinical-psychological study. Am J Psychiatry. 1952;108(12):896–900.CrossRefPubMed
125.
Mendelson SD. The current status of the platelet 5-HT(2A) receptor in depression. J Affect Disord. 2000;57(1–3):13–24.CrossRefPubMed
126.
Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry. 2002;159(3):419–29.CrossRefPubMed
127.
Shelton RC, Sanders-Bush E, Manier DH, Lewis DA. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009;158(4):1406–15.CrossRefPubMed
128.
Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F] altanserin positron emission tomography. Neuropsychopharmacology. 2004;29(12):2235–41.CrossRefPubMed
129.
Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry. 2003;160(1):90–9.CrossRefPubMed
130.
Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C] MDL 100,907. Am J Psychiatry. 2006;163(9):1580–7.CrossRefPubMed
131.
Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012;91(2):201–14.CrossRefPubMed
132.
Brandrup E, Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr Scand. 1977;55(2):127–41.CrossRefPubMed
133.
Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010;30(9):1140–4.CrossRefPubMed
134.
Nic Dhonnchadha BA, Hascoët M, Jolliet P, Bourin M. Evidence for a 5- HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res. 2003;147(1–2):175–84.CrossRefPubMed
135.
Ripoll N, Nic Dhonnchadha BA, Sébille V, Bourin M, Hascoët M. The four- plates test-retest paradigm to discriminate anxiolytic effects. Psychopharmacology. 2005;180(1):73–83.CrossRefPubMed
136.
Massé F, Hascoët M, Bourin M. Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice. Eur Neuropsychopharmacol. 2007;17(6–7):483–91.CrossRefPubMed
137.
138.
Botanas CJ, de la Peña JB, Kim HJ, Lee YS, Cheong JH. Methoxetamine: a foe or friend? Neurochem Int. 2019;122:1–7.CrossRefPubMed
139.
140.
141.
•• Calvey T, Howells FM. An introduction to psychedelic neuroscience. Prog Brain Res. 2018;242:1–23. This paper gives an overview of the neurobiological mechanisms of psychedelic drugs and the eventual resulting changes in brain activity.CrossRefPubMed
142.
Mason O, Morgan CJA, Dhiman SK, Patel A, Parti N, Curran HV. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med. 2009;39(6):951–6.CrossRefPubMed
143.
144.
Dong H, Yang C, Shen Y, Liu L, Liu M, Hao W. Effects of ketamine use on psy4hotic disorders and symptoms in male, methamphetamine-dependent subjects. Am J Drug Alcohol Abuse. 2019;14:1–9.
145.
146.
•• De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018;242:69–96. This paper reviewed the pharmacology of psychedelic drugs, reporting the clinical evidence of their therapeutic potentials in mood disorders.CrossRefPubMed
147.
Bonhoeffer K. Klinische und anatomische Beitrage zur Kennt- nis der Alkoholdelirien. Mschr Psychiat Neurol. 1897:6–41.
148.
Martinotti G, Di Nicola M, Quattrone D, Santacroce R, Schifano F, Murray R, et al. Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma. J Psychopathol. 2015;21:400–5.
149.
Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333–60.CrossRefPubMed
150.
• Murnane KS. The renaissance in psychedelic research: what do preclinical models have to offer. Prog Brain Res. 2018;242:25–67. This chapter documents the current status of psychedelic research, with the thematic argument that new preclinical studies would benefit this field.CrossRefPubMed
151.
Davidson C, Schifano F. The potential utility of some legal highs in CNS disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:267–74.CrossRef
152.
•• Schifano F, Orsolini L, Papanti D, Corkery J. NPS: medical consequences associated with their intake. Curr Top Behav Neurosci. 2017;32:351–80. https://​doi.​org/​10.​1007/​7854_​2016_​15 This paper provides an overview of the clinical and pharmacological issues relating to some NPS categories, considering their effects/toxicity and the management of their adverse events.CrossRefPubMed
153.
Van Buskirk J, Griffiths P, Farrell M, Degenhardt L. Trends in new psychoactive substances from surface and “dark” net monitoring. Lancet Psychiatry. 2017;4(1):16–8.CrossRefPubMed
154.
Simonato P, Corazza O, Santonastaso P, Corkery J, Deluca P, Davey Z, et al. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey. Hum Psychopharmacol. 2013;28(4):324–31.CrossRefPubMed
Metadaten
Titel
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
verfasst von
Fabrizio Schifano
Flavia Napoletano
Stefania Chiappini
Laura Orsolini
Amira Guirguis
John Martin Corkery
Stefania Bonaccorso
Angelo Ricciardi
Norbert Scherbaum
Alessandro Vento
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Current Addiction Reports / Ausgabe 2/2019
Elektronische ISSN: 2196-2952
DOI
https://doi.org/10.1007/s40429-019-00249-z

Weitere Artikel der Ausgabe 2/2019

Mobile Applications for the Treatment of Tobacco Use and Dependence

  • Tobacco (K Garrison, Section Editor)

Social Media for Tobacco Smoking Cessation Intervention: A Review of the Literature

  • Tobacco (K Garrison, Section Editor)

Dopamine and Gambling Disorder: Prospects for Personalized Treatment

  • Gambling (L Clark, Section Editor)

E-Cigarettes: Tobacco Policy and Regulation

  • Tobacco (K Garrison, Section Editor)

Gambling Marketing from 2014 to 2018: a Literature Review

  • Open Access
  • Gambling (L Clark, Section Editor)

A Review of the Use and Appeal of Flavored Electronic Cigarettes

  • Tobacco (K Garrison, Section Editor)

Neu im Fachgebiet Psychiatrie

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Depressive Senioren fahren besonders riskant

Beim Autofahren machen ältere Depressive häufiger eine Vollbremsung, gehen öfter zu schnell in Kurven und halten sich seltener an Tempolimits als Senioren ohne Depression. Offenbar scheint eine Depression eine riskante Fahrweise im Alter zu verstärken.

Verhaltenstherapie plus Stimulanz reduziert Binge Eating

Die Kombination von kognitiver Verhaltenstherapie plus Lisdexamfetamin bringt Personen mit Binge-Eating-Störung deutlich häufiger in Remission als die jeweiligen Einzeltherapien. Zudem nimmt das Gewicht der Betroffenen spürbar ab.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise